J.P. Morgan: Healthcare Investment Banking Activity Remains Robust
Mergers and acquisitions in the healthcare sector, particularly cross-border deals, have accelerated. A J.P. Morgan report highlights patent cliffs and technology adoption as drivers of sector dynamism.
Halfway through 2026, investment banking activity within the healthcare sector is demonstrating significant robustness, with merger and acquisition (M&A) levels remaining high despite global volatility. According to a J.P. Morgan report, strategic urgency driven by patent cliffs and pipeline gaps, coupled with strong corporate balance sheets, is fueling substantial deal activity.
Biopharmaceutical and biotech companies have been actively seeking to bolster their product pipelines through strategic acquisitions. For instance, Gilead's nearly $5 billion acquisition of Tubulis, for which J.P. Morgan served as financial advisor to Tubulis, marked a significant European private, clinical-stage oncology deal. Jerry Lee, global co-head of Healthcare Investment Banking at J.P. Morgan, also cited Sun Pharma's $11.75 billion acquisition of Organon as an example of a megadeal.
Adoption of artificial intelligence (AI) has also accelerated within the healthcare industry, with companies pursuing acquisitions, partnerships, and capital investments to enhance competitive positioning and drive innovation. Furthermore, supply chain resilience and regulatory complexity are reshaping strategies, leading to diversification of supply chains and optimization of business portfolios.
Cross-border collaboration is also on the rise, with companies actively seeking innovative technologies from international markets. J.P. Morgan acted as exclusive financial advisor to GN Store Nord in the sale of its Hearing division to Italy-based Amplifon, an example of a transaction aligned with this growing trend. The report anticipates that strategic urgency and strong balance sheets will continue to propel M&A activity, sustaining a vibrant capital markets environment.